Tuesday। 17 November। 2026
আগামীর সময়
Tuesday। 17 November। 2026
Agamir Somoy
  • Latest
  • Bangladesh
  • Business
  • Chattogram
  • District
  • World
  • Environment
  • Entertainment
  • Sports
  • Feature
  • OP-ED
  • Misc
  • Success Story
  • Religion
BN
  • Latest
  • Bangladesh
  • Business
  • Chattogram
  • District
  • World
  • Environment
  • Entertainment
  • Sports
  • Feature
  • OP-ED
  • Misc
  • BN
লোড হচ্ছে…

Chief Editor & Publisher: Abdus Sattar Miazi

Editor: Mustafa Mamun

Agamir Somoy English Logo
About UsContactTerms of ServicePrivacy PolicyTeam

EDB Trade Centre (Level-6 &7) 93 Kazi Nazrul Islam Avenue Karwanbazar, Dhaka-1215.

Contact: +880 9666 771010

Advertise: +880 1755 651164

[email protected]

© 2026 | Dainik Agamir Somoy. All rights reserved.

আগামীর সময় Share Market

Renata expands its presence in European market

Economic Correspondent
agamir somoy
Published: 17 November 2026, 13:21
শেয়ার করুন:
Renata expands its presence in European market

Logo

Renata PLC, a publicly listed pharmaceutical manufacturer, has maintained its growth in profitability while expanding its business in domestic and international markets. The company has recently started marketing a new medicine in the Netherlands. Meanwhile, its earnings per share increased by 37 percent in the first quarter (July to September) of the current 2026-27 fiscal year compared to the same period last year. Earlier, the company announced a 55 percent cash dividend for shareholders for the 2025-26 fiscal year.

According to information published on the Dhaka Stock Exchange (DSE) website, Renata has started marketing Amantadine Hydrochloride capsules in the Netherlands. The medicine is used to relieve symptoms of Parkinson’s disease. Each pack of the 100 mg medicine contains 56 capsules. In Bangladesh, the company markets the same medicine under the brand name Montadine.

The medicine is manufactured at Renata’s production facility in Rajendrapur. The company is further expanding its presence in the European market by supplying the medicine to the Netherlands from this facility, which has been approved under the European Union’s Good Manufacturing Practice (EU GMP) standards.

Meanwhile, Renata’s earnings per share (EPS) stood at Tk 8.87 in the first quarter of the current fiscal year. The figure was Tk 6.47 during the same period of the previous fiscal year. This represents an increase of Tk 2.40 per share or approximately 37 percent in one year. As of September 30, the company’s net asset value per share (NAVPS) stood at Tk 339.31.

Earlier, Renata’s board of directors announced a 55 percent cash dividend for shareholders based on its performance in the 2025-26 fiscal year. The company reported earnings per share of Tk 31.76 for that fiscal year. Its net asset value per share stood at Tk 329.19 as of June 30. The company had also paid a 55 percent cash dividend for the previous 2024-25 fiscal year, when its earnings per share stood at Tk 19.36.

The company’s annual general meeting (AGM) will be held on December 19 to seek shareholders’ approval for the declared dividend and other matters. The record date for the meeting was set for November 15.

Dhaka Stock ExchangeRenata PLCEarnings per shareCash dividendAnnual general meetingQ1 earningsParkinson's medicineNetherlands export EU GMPPharmaceutical manufacturer
    আগামীর সময় ইপেপার
    শেয়ার করুন: